A Phase 3 interventional study of Neridronic acid 100 mg and Placebo in Complex Regional Pain Syndrome (CRPS), sponsored by Grünenthal GmbH. Terminated at 71 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-06.
Sponsored by Grünenthal GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Complex Regional Pain Syndromes with a site in United States — 20 open to participants now, 22 under way, 2 of them phase 3. Complex Regional Pain Syndromes · United States.
Among the 88 studies in Complex Regional Pain Syndromes with a site in United States, this one is the 8th largest by enrollment of the 67 interventional ones that give a count, is one of 10 that started in 2018, is one of 12 in phase 3, and was the 48th registered.
206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.
Browse Complex Regional Pain Syndromes studies →20 of the 88 studies in Complex Regional Pain Syndromes with a site in United States are open now. Recruiting first, the newest first:
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
Scripps Health · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Complex Regional Pain Syndromes studies recruiting now, 17 (44%) set no upper age limit and 16 (41%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 4
First in 2000; this study’s year is marked. 10 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 182 is above the median of 40 across 152 interventional studies indexed under Complex Regional Pain Syndromes.
Median enrollment 30 across the 67 interventional studies, 60 across the 21 observational. Of the 56 that completed or were terminated, 29 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 88 have an industry lead sponsor. The 10 most frequent:
Grünenthal GmbH is the lead sponsor of 69 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
Grünenthal GmbH has 3 studies filed under Complex Regional Pain Syndromes — fewer than ten, so there is no comparison to draw.
8 of the studies in Complex Regional Pain Syndromes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06798493Hospital for Special Surgery, New YorkCSS-SR Validation Study | 2026-12-29 |
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
| NCT05477004Theresa LiiObservational Study of Ketamine Infusions for the Treatment of Chronic Pain | 2026-12-31 |
| NCT05777889Hospital for Special Surgery, New YorkInfrared Images for Spinal Cord Stimulation in Complex Regional Pain Syndrome Patients | 2027-02 |
| NCT05814497Children's Hospital Medical Center, CincinnatiSupraspinal Processing of Sensory Aspects of Pain | 2027-06-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 88 studies in Complex Regional Pain Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this trial was to investigate the efficacy and safety of intravenous neridronic acid in subjects with Complex Regional Pain Syndrome (CRPS).
The trial consisted of an Enrollment Period lasting up to 60 days, Treatment Period A consisting of 4 infusions (neridronic acid or placebo) over 10 days, and a Follow-up Period 1 until Week 26.
At Week 26, participants not meeting the pre-specified criteria to continue into Treatment Period B continued in Follow-up Period 2 until Week 52. Participants meeting the pre-specified criteria entered the open-label Treatment Period B with 4 additional infusions (neridronic acid) over 10 days and follow-up visits until Week 52.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Criteria to continue into Treatment Period B
The following exclusion criteria are not met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration. The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B.
Drug: Neridronic acid 100 mg
Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
Drug: Placebo
100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
Glass vials with matching placebo.
Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary)
In the Baseline Phase and in Treatment Period A/Follow-up Period 1, participants were asked to assessed their average CRPS-related pain on an 11-point numerical rating scale (NRS) - from 0 = "no pain" to 10 = "pain as bad as you can imagine" and report it once daily (in the evening, 24-hour recall) in an electronic diary. Changes from baseline (average for the Baseline Phase) to the weekly average for Week 12 were calculated.
Time frame: From the Baseline Phase (Day -7 to Day -1) to Week 12
Change From Baseline to Week 26 in the Average Pain Intensity Recorded on the Tablet Computer.
11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). Changes from baseline to Week 26 were planned to be analyzed.
Time frame: From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26)
Pain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 12, Recorded on the Tablet Computer.
11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). The number of participants with response at Week 12 was planned to be determined.
Time frame: From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)
Pain Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Average Pain Intensity at Week 26, Recorded on the Tablet Computer.
11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). The number of participants with response at Week 26 was planned to be determined.
Time frame: From baseline (Visit 2 [Day 1]) to Visit 11 (Week 26)
Change From Baseline to Week 12 in the Pain Intensity Level of Dynamic Mechanical Allodynia (DMA).
Dynamic mechanical allodynia: a tactile stimulus is applied in a single sweeping motion (1 cm to 2 cm length) on the skin on the affected limb. The participants are asked to judge the stimulus intensity by means of an NRS (0 to 10). "0" in this case means "no pain". Each "pricking", "stinging" or "burning" sensation is defined as a painful sensation, which should always be evaluated by giving a value greater than "0". "10" corresponds to the individual maximum pain imaginable. Change from baseline was planned to analyzed.
Time frame: From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)
Change From Baseline to Week 12 in the Pressure Pain Threshold (PPT) Ratio for the Thenar Muscle/Abductor Hallucis Muscle.
Pressure pain threshold: using a pressure algometer (contact area 1 cm2), the threshold for pressure-induced pain is measured on the thenar muscle/abductor hallucis muscle in 3 series of slowly increasing stimulus intensities (at a rate of about 50 kPa/s). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The ratio of the thresholds of the affected limb versus the unaffected limb was planned to be calculated.
Time frame: From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)
Change From Baseline to Week 12 in the Ratio of the Figure of Eight Measurements of the Affected Limb Versus the Unaffected Limb.
In participants with the CRPS sign of edema on the CRPS severity score at baseline, circumference of the hand or foot will be measured by the investigator with measurement tape using the figure-of-eight method at both the affected limb and the contralateral unaffected limb. Each measurement will be performed 3 times. The average of the 3 measurements will be used for further analysis. The ratio of the averages of the affected limb versus the unaffected limb was planned to be calculated and used for the determination of the change from baseline.
Time frame: From baseline (Visit 2 [Day 1]) to Visit 8 (Week 12)
First participant enrollment on 30 May 2018. After a pooled interim analysis of primary endpoint data of studies KF7013-02 and KF7013-04 (NCT03560986), recruitment was stopped as interim results indicated futility. Last participant's last assessment was on 31 July 2019.
| Milestone | Neridronic Acid - Treatment Period A/B | Placebo - Treatment Period A/B |
|---|---|---|
| Started | 28 | 29 |
| Treatment period a completers | 26 | 27 |
| Completed | 7 | 7 |
| Not completed | 21 | 22 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Other reasons for discontinuation | 17 | 21 |
| Milestone | Neridronic Acid - Treatment Period A/B | Placebo - Treatment Period A/B |
|---|---|---|
| Started | 5 | 7 |
| Treatment period b completers | 4 | 6 |
| Completed | 0 | 0 |
| Not completed | 5 | 7 |
| Withdrew: Other reasons for discontinuation | 5 | 7 |
In the Baseline Phase and in Treatment Period A/Follow-up Period 1, participants were asked to assessed their average CRPS-related pain on an 11-point numerical rating scale (NRS) - from 0 = "no pain" to 10 = "pain as bad as you can imagine" and report it once daily (in the evening, 24-hour recall) in an electronic diary. Changes from baseline (average for the Baseline Phase) to the weekly average for Week 12 were calculated.
| units on a scale | Neridronic Acid - Treatment Period A | Placebo - Treatment Period A |
|---|---|---|
| Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary) | -1.23 ± 0.310 | -0.16 ± 0.305 |
11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). Changes from baseline to Week 26 were planned to be analyzed.
No measurements were reported for this outcome.
11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). The number of participants with response at Week 12 was planned to be determined.
No measurements were reported for this outcome.
11-point NRS - from 0 = "no pain" to 10 = "pain as bad as you can imagine" - reported at the visits on a tablet computer (24-hour recall). The number of participants with response at Week 26 was planned to be determined.
No measurements were reported for this outcome.
Dynamic mechanical allodynia: a tactile stimulus is applied in a single sweeping motion (1 cm to 2 cm length) on the skin on the affected limb. The participants are asked to judge the stimulus intensity by means of an NRS (0 to 10). "0" in this case means "no pain". Each "pricking", "stinging" or "burning" sensation is defined as a painful sensation, which should always be evaluated by giving a value greater than "0". "10" corresponds to the individual maximum pain imaginable. Change from baseline was planned to analyzed.
No measurements were reported for this outcome.
Pressure pain threshold: using a pressure algometer (contact area 1 cm2), the threshold for pressure-induced pain is measured on the thenar muscle/abductor hallucis muscle in 3 series of slowly increasing stimulus intensities (at a rate of about 50 kPa/s). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The ratio of the thresholds of the affected limb versus the unaffected limb was planned to be calculated.
No measurements were reported for this outcome.
In participants with the CRPS sign of edema on the CRPS severity score at baseline, circumference of the hand or foot will be measured by the investigator with measurement tape using the figure-of-eight method at both the affected limb and the contralateral unaffected limb. Each measurement will be performed 3 times. The average of the 3 measurements will be used for further analysis. The ratio of the averages of the affected limb versus the unaffected limb was planned to be calculated and used for the determination of the change from baseline.
No measurements were reported for this outcome.
Collected over Adverse events were documented from the time of enrollment (i.e., the time the informed consent form was signed) up to the time of the last protocol scheduled contact, i.e., date of last visit/contact (could be a phone call, e.g., in case of withdrawal). Only treatment emergent adverse events (TEAEs, i.e., those reported from baseline (after first administration of study medication) are reported in the tables below.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baseline to Week 26: Placebo TPA | 0/29 (0%) | 0/29 (0%) | 15/29 (51.7%) |
| Baseline to Week 26: Neridronic Acid TPA | 0/28 (0%) | 2/28 (7.1%) | 16/28 (57.1%) |
| Week 26 to Week 52: Placebo TPA | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Week 26 to Week 52: Placebo TPA, Neridronic Acid TPB | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Week 26 to Week 52: Neridronic Acid TPA | 0/23 (0%) | 0/23 (0%) | 1/23 (4.3%) |
| Week 26 to Week 52: Neridronic Acid TPA, Neridronic Acid TPB | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Event | Baseline to Week 26: Placebo TPA | Baseline to Week 26: Neridronic Acid TPA | Week 26 to Week 52: Placebo TPA | Week 26 to Week 52: Placebo TPA, Neridronic Acid TPB | Week 26 to Week 52: Neridronic Acid TPA | Week 26 to Week 52: Neridronic Acid TPA, Neridronic Acid TPB |
|---|---|---|---|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 0/29 | 1/28 | 0/22 | 0/7 | 0/23 | 0/5 |
| Suicidal ideationPsychiatric disorders | 0/29 | 1/28 | 0/22 | 0/7 | 0/23 | 0/5 |
| Event | Baseline to Week 26: Placebo TPA | Baseline to Week 26: Neridronic Acid TPA | Week 26 to Week 52: Placebo TPA | Week 26 to Week 52: Placebo TPA, Neridronic Acid TPB | Week 26 to Week 52: Neridronic Acid TPA | Week 26 to Week 52: Neridronic Acid TPA, Neridronic Acid TPB |
|---|---|---|---|---|---|---|
| Acute phase reactionGeneral disorders | 0/29 | 4/28 | 0/22 | 3/7 | 0/23 | 0/5 |
| Oedema peripheralGeneral disorders | 0/29 | 2/28 | 0/22 | 1/7 | 0/23 | 0/5 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/29 | 0/28 | 0/22 | 1/7 | 0/23 | 0/5 |
| Urinary tract infectionInfections and infestations | 0/29 | 0/28 | 0/22 | 1/7 | 0/23 | 0/5 |
| FallInjury, poisoning and procedural complications | 0/29 | 0/28 | 0/22 | 1/7 | 0/23 | 0/5 |
| Back painMusculoskeletal and connective tissue disorders | 0/29 | 0/28 | 0/22 | 1/7 | 0/23 | 0/5 |
| NauseaGastrointestinal disorders | 4/29 | 2/28 | 0/22 | 0/7 | 0/23 | 0/5 |
| HeadacheNervous system disorders | 3/29 | 2/28 | 0/22 | 0/7 | 0/23 | 0/5 |
| DiarrhoeaGastrointestinal disorders | 1/29 | 2/28 | 0/22 | 0/7 | 0/23 | 0/5 |
| NasopharyngitisInfections and infestations | 0/29 | 2/28 | 0/22 | 0/7 | 0/23 | 0/5 |
Safety Set; all participants treated in Treatment Period A.
| Age, Continuous(years) | Neridronic Acid - Treatment Period A | Placebo - Treatment Period A | Total |
|---|---|---|---|
| Mean | 46.1 ± 11.0 | 49.4 ± 12.1 | 47.8 ± 11.6 |
| Age, Customized(Participants) | Neridronic Acid - Treatment Period A | Placebo - Treatment Period A | Total |
|---|---|---|---|
| < 18 years | 0 | 0 | 0 |
| From 18 to <65 years | 28 | 25 | 53 |
| From 65 to <85 years | 0 | 4 | 4 |
| 85 years and above | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Neridronic Acid - Treatment Period A | Placebo - Treatment Period A | Total |
|---|---|---|---|
| Female | 22 | 22 | 44 |
| Male | 6 | 7 | 13 |
| Race (NIH/OMB)(Participants) | Neridronic Acid - Treatment Period A | Placebo - Treatment Period A | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 24 | 28 | 52 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Neridronic Acid - Treatment Period A | Placebo - Treatment Period A | Total |
|---|---|---|---|
| New Zealand | 0 | 1 | 1 |
| South Korea | 2 | 0 | 2 |
| United States | 22 | 22 | 44 |
| Australia | 0 | 1 | 1 |
| Germany | 1 | 0 | 1 |
| Spain | 3 | 5 | 8 |
| Complex regional pain syndrome (CRPS) type(Participants) | Neridronic Acid - Treatment Period A | Placebo - Treatment Period A | Total |
|---|---|---|---|
| CRPS Type I | 25 | 21 | 46 |
| CRPS Type II | 3 | 8 | 11 |
| Time since onset of CRPS symptoms(months) | Neridronic Acid - Treatment Period A | Placebo - Treatment Period A | Total |
|---|---|---|---|
| Median | 17.72 (7.60 to 22.02) | 13.47 (8.20 to 18.87) | 14.23 (7.80 to 20.80) |
| Time since diagnosis of CRPS(months) | Neridronic Acid - Treatment Period A | Placebo - Treatment Period A | Total |
|---|---|---|---|
| Median | 9.15 (4.82 to 16.07) | 11.37 (3.30 to 17.87) | 10.37 (4.30 to 16.67) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Information available on the Grünenthal Group Web Site (see URL below for details); according to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Data Sharing Principles.
Supporting information: Study protocol, Statistical analysis plan
Data sharing details ↗ · www.grunenthal.com
Ran from May 2018 to primary completion in Jul 2019, 14 months.
Results were first posted in Aug 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Neridronic acid
Complex Regional Pain Syndromes →